LACK OF COVALENT BINDING TO RAT LIVER DNA OF THE HYPOLIPIDEMIC DRUGS CLOFIBRATE AND FENOFIBRATE NLM AIDSLINE Important note: Information in this article was accurate in 1981. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


LACK OF COVALENT BINDING TO RAT LIVER DNA OF THE HYPOLIPIDEMIC DRUGS CLOFIBRATE AND FENOFIBRATE

Toxicol Lett; 7(4/5):305-310 1981. Unique Identifier : AIDSLINE ICDB/81612389
Von Daniken A; Lutz WK; Schlatter C; Inst. Toxicology, Swiss Federal Inst. Technology, Schwerzenbach; CH-8603, Switzerland

Abstract: Labeled clofibric or fenofibric acid was administered po to Sprague-Dawley derived SIV 50 rats, and 10 hr later, the animals were sacrificed and the nuclear DNA and protein were isolated from the livers. 14C-Label was detected in protein (9-78 disintegrations/min); however, radioactivity levels in the DNA were just above the limit of detection for the high dose of clofibric acid and were not detectable at all for fenofibric acid. Oral administration of clofibric acid labeled at the terminal carboxyl group resulted in 0.85% of the dose exhaled within 10 hr as 14CO2. The results of these experiments suggested that the minute radioactivity detected in the DNA after high-dose clofibric acid administration may have been due to the biosynthetic incorporation of radioactivity rather than to covalent binding of the drug to DNA. (19 Refs)
Keywords: JOURNAL ARTICLEKWDjournalarticle
810630
M8160007

Copyright © 1981 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1981. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1981. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .